Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Rises By 53.8%

17 Jan 2026, 03:38 by Michael Walen · The Markets Daily

Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 3,790,158 shares, a growth of 53.8% from the December 15th total of 2,464,343 shares. Based on an average daily trading volume, of 785,510 shares, the short-interest ratio is presently 4.8 days. Approximately 10.4% of the company’s shares are short sold. Approximately 10.4% of the company’s shares are short sold. Based on an average daily trading volume, of 785,510 shares, the short-interest ratio is presently 4.8 days.

Insider Activity at Disc Medicine

In related news, Director Kevin Bitterman sold 68,923 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $91.24, for a total value of $6,288,534.52. Following the completion of the sale, the director owned 14,161 shares in the company, valued at approximately $1,292,049.64. The trade was a 82.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jonathan Yen-Wen Yu sold 30,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $84.70, for a total value of $2,541,000.00. Following the completion of the transaction, the chief operating officer directly owned 40,555 shares in the company, valued at approximately $3,435,008.50. This trade represents a 42.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 274,470 shares of company stock worth $24,896,430 over the last quarter. 3.64% of the stock is owned by insiders.

Hedge Funds Weigh In On Disc Medicine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. Aster Capital Management DIFC Ltd purchased a new position in shares of Disc Medicine in the third quarter worth about $38,000. CWM LLC raised its position in Disc Medicine by 213.5% during the 2nd quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after buying an additional 711 shares during the last quarter. Avanza Fonder AB purchased a new position in Disc Medicine during the 2nd quarter worth approximately $57,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Disc Medicine by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,338 shares of the company’s stock valued at $71,000 after acquiring an additional 181 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Disc Medicine by 8.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock valued at $133,000 after acquiring an additional 206 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Down 0.2%

Shares of NASDAQ:IRON traded down $0.11 during trading on Friday, reaching $70.93. The stock had a trading volume of 454,807 shares, compared to its average volume of 643,055. The firm’s 50-day simple moving average is $85.55 and its 200 day simple moving average is $72.42. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. Disc Medicine has a one year low of $30.82 and a one year high of $99.50. The company has a market capitalization of $2.68 billion, a P/E ratio of -13.26 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON – Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.29). As a group, research analysts expect that Disc Medicine will post -4.07 EPS for the current fiscal year.

Analyst Ratings Changes

IRON has been the topic of several research reports. Stifel Nicolaus initiated coverage on Disc Medicine in a report on Monday, November 3rd. They issued a “buy” rating and a $125.00 price objective for the company. Truist Financial increased their target price on shares of Disc Medicine from $86.00 to $114.00 and gave the stock a “buy” rating in a report on Monday, November 10th. UBS Group restated an “overweight” rating on shares of Disc Medicine in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, October 8th. Finally, National Bankshares set a $153.00 price objective on shares of Disc Medicine in a research note on Friday, October 17th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $119.45.

Read Our Latest Stock Report on IRON

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.